Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius Medical Care, and PerkinElmer PR Newswire NEW YORK, November 28, 2013 NEW YORK, November 28, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), Sirona Dental Systems, Inc. (NASDAQ: SIRO), Centene Corp. (NYSE: CNC), Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS), and PerkinElmer, Inc. (NYSE: PKI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Celgene Corporation Research Report On November 22, 2013, Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (Celgene), announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. According to Celgene, it expects the European Commission, which generally follows the recommendation of the CHMP, to make the final decision within two to three months. Alan Colowick, MD, President of Celgene Europe, the Middle East and Africa (EMEA), said, "The positive CHMP opinion on ABRAXANE with gemcitabine for metastatic pancreatic cancer is a significant step toward bringing the first new treatment option in many years to people diagnosed with this deadly disease, which has seen multiple clinical trial failures over the years. Following a positive decision by the European Commission within the next few months, we hope to begin the important work of helping physicians and patients gain access to ABRAXANE plus gemcitabine, which has demonstrated statistically significant and clinically meaningful improvements in overall survival compared to gemcitabine alone, as reported recently in the New England Journal of Medicine." The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/7f47_CELG -- Sirona Dental Systems, Inc. Research Report On November 25, 2013, Sirona Dental Systems, Inc.'s (Sirona) stock declined 4.12%, ending the day at $67.30. Over the previous three trading sessions, shares of Sirona declined 7.25% compared to the Nasdaq Composite which gained 1.87% during the same period. The Full Research Report on Sirona Dental Systems, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/08e7_SIRO -- Centene Corp. Research Report On November 25, 2013, Centene Corp.'s (Centene) stock rose 1.54%, ending the day at $59.43. Over the previous three trading sessions, shares of Centene rose 3.66% compared to the S&P 500 which gained 1.19% during the same period. The Full Research Report on Centene Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/e85d_CNC -- Fresenius Medical Care AG & Co. (ADR) Research Report On November 25, 2013, Reuters reported that the shares of Fresenius Medical Care AG & Co. (ADR) (Fresenius Medical Care) rose after a statement by a U.S. healthcare agency, which informed of its intention to phase in reimbursement cuts rather than introduce them in one hit in 2014. Reuters further reported that Medicare, the U.S. government healthcare program for elderly and disabled people, will spread a 9.4% cut, initially proposed to take effect in 2014, over the next three to four years. The Reuters report also informed that Medicare reimburses Fresenius Medical Care and other dialysis providers for the cost of treating kidney patients covered by the Medicare program. Commenting on the phased-in cuts, Reuters reported that each year, the cuts will be no worse than routine annual mark-ups to adjust for inflation, making Medicare payments remain flat at worst, for at least the next two years. The Full Research Report on Fresenius Medical Care AG & Co. (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/dfd9_FMS -- PerkinElmer, Inc. Research Report On November 21, 2013, PerkinElmer, Inc. (PerkinElmer) announced the appointment of Jon DiVincenzo as President, Environmental Health and Senior Vice President of PerkinElmer, effective December 2, 2013. The Company reported that in his new role, DiVincenzo will have overall leadership responsibility for the Company's Environmental Health business. Commenting on the appointment, Robert F. Friel, Chairman and CEO, said, "We are delighted to welcome Jon to PerkinElmer, further expanding the capabilities of our leadership team. Jon's deep market knowledge and strong track record of building and growing successful global businesses will enable him to play a pivotal role in helping PerkinElmer accelerate growth and innovation." PerkinElmer further added that Maurice "Dusty" Tenney, who has led the Environmental Health business for four years, will transition to a newly created position overseeing global operations and customer logistics for the Corporation. The Full Research Report on PerkinElmer, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/2016_PKI ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius
Press spacebar to pause and continue. Press esc to stop.